Program
Memantine
Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.
Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.
Drug pageMemantine: every studyMany companies study it; this page follows only the 27 they lead. All 198 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 130 open or running | phase 4since Jun 6, 2006 | Dec 1, 2004 | none ahead |
| H. Lundbeckits history only | 60 open or running | phase 4since Mar 3, 2009 | Mar 3, 2009 | none ahead |
| Merz Pharmaits history only | 40 open or running | phase 4since Mar 27, 2008 | Feb 14, 2008 | none ahead |
| Carnot Laboratoriesits history only | 10 open or running | phase 4since Feb 11, 2026 | Feb 11, 2026 | none ahead |
| Gedeon Richter Plc.its history only | 10 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Apr 18, 2017 | Apr 18, 2017 | none ahead |
| Mendel AIits history only | 10 open or running | phase 3since Jan 30, 2021 | Jan 30, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Dec 1, 2004.
- Mar 27, 2008Phase 4 study in Alzheimer DiseaseMerz Pharma · NCT00649220 · 19 enrolled · Germany
- Dec 5, 2008Phase 3 study in Alzheimer DiseaseMerz Pharma · NCT00804271 · 487 enrolled · Germany
- Mar 3, 2009H. Lundbeck’s first studies: 2 phase 4 studiesNew to H. LundbeckH. Lundbeck · NCT00855686, NCT00862940
- Mar 5, 20092 phase 3 studies in Alzheimer DiseaseH. Lundbeck · NCT00857649, NCT00857233
- Mar 30, 2009Phase 2 study in Autistic DisorderAbbVie · NCT00872898 · 124 enrolled · United States
- Dec 15, 2010Phase 2 study in Memory DisordersMerz Pharma · NCT01261741 · 299 enrolled · Germany, United Kingdom
- May 3, 20123 phase 2 studiesAbbVie · NCT01592786, NCT01592773, NCT01592747
- Nov 15, 2013Gedeon Richter Plc.’s first study: phase 1 study in ObesityNew to Gedeon Richter Plc.Gedeon Richter Plc. · NCT02001584 · United Kingdom
- Nov 26, 2013Phase 2 study in Autistic DisorderAbbVie · NCT01999894 · 102 enrolled · United States
- Sep 16, 2015Phase 4 study in Alzheimer DiseaseH. Lundbeck · NCT02553928 · 62 enrolled · China
- Apr 18, 2017Geropharm’s first study: phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsNew to GeropharmGeropharm · NCT03121820 · 18 enrolled · Russian Federation
- Sep 12, 2018Phase 1 study in HealthyH. Lundbeck · NCT03670095 · 64 enrolled · China
- Jan 30, 2021Mendel AI’s first study: phase 3 study in Cancer PainNew to Mendel AIMendel AI · NCT04737967 · 60 enrolled · Egypt
- Feb 11, 2026Carnot Laboratories’ first study: phase 4 study in Alzheimer DiseaseNew to Carnot LaboratoriesCarnot Laboratories · NCT07417670 · 105 enrolled · Mexico
TargetBeta
“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esketaminerule | Johnson & Johnson | phase 4 | 51 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07417670Alzheimer Disease · Mexico | 4 | Completed | Carnot Laboratories | Aug 12, 2025 | 105 |
| NCT04737967Cancer Pain · Egypt | 3 | UNKNOWN | Mendel AI | Aug 15, 2021 | 60 |
| NCT03670095Healthy · China | 1 | Completed | H. Lundbeck | Dec 24, 2018 | 64 |
| NCT03121820Bioequivalence, AUC, Cmax, Pharmacokinetics · Russian Federation | 1 | Completed | Geropharm | Nov 19, 2016 | 18 |
| NCT02553928Alzheimer Disease · China | 4 | Completed | H. Lundbeck | Jul 2016 | 62 |
| NCT01999894Autistic Disorder · United States | 2 | Completed | AbbVie | Feb 2013 | 102 |
| NCT02001584Obesity · United Kingdom | 1 | Completed | Gedeon Richter Plc. | May 2014 | |
| NCT01592786Autism Spectrum Disorder · United States, Australia, Belgium and more | 2 | Completed | AbbVie | Jul 2013 | 906 |
| NCT01592773Autism Spectrum Disorder · United States, Belgium, Canada and more | 2 | Terminated | AbbVie | Jan 2014 | 747 |
| NCT01592747Autistic Disorder · United States, Belgium, Colombia and more | 2 | Completed | AbbVie | Sep 2013 | 479 |
| NCT01261741Memory Disorders · Germany, United Kingdom | 2 | Completed | Merz Pharma | Aug 2011 | 299 |
| NCT00872898Autistic Disorder · United States | 2 | Completed | AbbVie | Aug 2012 | 124 |
| NCT00862940Alzheimer Disease | 4 | Completed | H. Lundbeck | Feb 2009 | 277 |
| NCT00857649Alzheimer Disease · Canada | 3 | Terminated | H. Lundbeck | Apr 2010 | 369 |
| NCT00857233Alzheimer Disease · Canada | 3 | Terminated | H. Lundbeck | Jul 2010 | 297 |
| NCT00855686Lewy Body Disease · Germany | 4 | Completed | H. Lundbeck | Dec 2008 | 199 |
| NCT00804271Alzheimer Disease · Germany | 3 | Completed | Merz Pharma | Nov 2009 | 487 |
| NCT00649220Alzheimer Disease · Germany | 4 | Terminated | Merz Pharma | May 2009 | 19 |
| NCT00624026Alzheimer Disease · Germany | 3 | Completed | Merz Pharma | Dec 2008 | 107 |
| NCT00469456Alzheimer Disease · Australia, New Zealand, South Africa | 4 | Completed | AbbVie | Nov 2008 | 265 |
| NCT00334906Alzheimer Disease · United States | 4 | Completed | AbbVie | Nov 2007 | 75 |
| NCT00322153Alzheimer Disease · United States, Argentina, Chile and more | 3 | Completed | AbbVie | Oct 2007 | 677 |
| NCT00168350Glaucoma, Open-Angle | 3 | Completed | AbbVie | Sep 2006 | 1,179 |
| NCT00141882Glaucoma, Open-Angle | 3 | Completed | AbbVie | Jan 2006 | 1,119 |
| NCT00106405Bipolar Disorder · United States | 2 | Completed | AbbVie | Nov 2005 | 35 |
| NCT00097942Schizophrenia · United States | 2 | Completed | AbbVie | Sep 2005 | 138 |
| NCT00097916Alzheimer Disease · United States | 3 | Completed | AbbVie | Apr 2006 | 34 |
How it is read
Names in the registry
- “Memantine”, 11 entries
- “Memantine Hydrochloride (HCl)”, 4 entries
- “memantine”, 3 entries
- “memantine HCl”, 3 entries
- “Memantine HCl”, 2 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 14 studies
- Autistic Disorder, 3 studies
- Autism Spectrum Disorder, 2 studies
- Glaucoma, Open-Angle, 2 studies
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.